Skip to main content

Advertisement

SpringerLink
Log in

Survivin: a potential prognostic marker and chemoradiotherapeutic target for colorectal cancer

  • Original Article
  • Published:
Irish Journal of Medical Science Aims and scope Submit manuscript

Abstract

Objective

The aim of our study was to explore the expression of survivin gene in colorectal cancer (CRC) and its possibility as a molecular target for CRC chemoradiotherapy.

Materials and methods

Immunohistochemistry was performed to detect the expression of survivin in 68 CRC specimens. The correlations between survivin expression and clinicopathological factors and prognosis were evaluated. RNA interference was employed to downregulate survivin expression. The effects of survivin downregulation on chemoradiotherapy of CRC cells were evaluated.

Results

The staining of survivin protein was strongly positive in the cytoplasm of CRC cells. Its expression was significantly correlated with tumor differentiation, Duke’s stage, lymph node metastasis. Moreover, the elevated survivin expression was an independent factor for predicting the prognosis of CRC patients. Survivin downregulation could also enhance chemosensitivity or radiosensitivity of colorectal cells.

Conclusions

Survivin might be an independent prognostic factor and a potential target for the chemoradiotherapy of CRC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  2. Shelton BK (2002) Introduction to colorectal cancer. Semin Oncol Nurs 18:2–12

    Article  PubMed  Google Scholar 

  3. Vanhoefer U (2005) Molecular mechanisms and targeting of colorectal cancer. Semin Oncol 32:7–10

    Article  PubMed  Google Scholar 

  4. Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64:7183–7190

    Article  CAS  PubMed  Google Scholar 

  5. Yang YL, Li XM (2000) The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10:169–177

    Article  CAS  PubMed  Google Scholar 

  6. Mita AC, Mita MM, Nawrocki ST et al (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14:5000–5005

    Article  CAS  PubMed  Google Scholar 

  7. Pennati M, Folini M, Zaffaroni N (2008) Targeting survivin in cancer therapy. Expert Opin Ther Targets 12:463–476

    Article  CAS  PubMed  Google Scholar 

  8. Wang YG, Chen KX, Wu GL et al (2005) An analysis: colon cancer mortality in Tianjin, China, from 1981 to 2000. World J Gastroenterol 11:895–898

    PubMed  Google Scholar 

  9. Carrato A (2008) Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res 2:S42–S46

    PubMed  Google Scholar 

  10. Aranha O, Benson AB 3rd (2007) Adjuvant therapy for colon cancer. Curr Gastroenterol Rep 9:415–421

    Article  PubMed  Google Scholar 

  11. Wei Y, Fan T, Yu M (2008) Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin 40:278–288

    Article  PubMed  Google Scholar 

  12. Srinivasula SM, Ashwell JD (2008) IAPs: what’s in a name? Mol Cell 30:123–135

    Article  CAS  PubMed  Google Scholar 

  13. Fulda S (2008) Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. Anticancer Agents Med Chem 8:533–539

    CAS  PubMed  Google Scholar 

  14. LaCasse EC, Mahoney DJ, Cheung HH et al (2008) IAP-targeted therapies for cancer. Oncogene 27:6252–6275

    Article  CAS  PubMed  Google Scholar 

  15. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61–70

    Article  CAS  PubMed  Google Scholar 

  16. Sampath J, Pelus LM (2007) Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 4:174–191

    Article  CAS  PubMed  Google Scholar 

  17. Ulukus EC, Kargi HA, Sis B et al (2007) Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Appl Immunohistochem Mol Morphol 15:31–37

    Article  CAS  PubMed  Google Scholar 

  18. Nassar A, Sexton D, Cotsonis G et al (2008) Survivin expression in breast carcinoma: correlation with apoptosis and prognosis. Appl Immunohistochem Mol Morphol 16:221–226

    Article  CAS  PubMed  Google Scholar 

  19. Sarela AI, Verbeke CS, Ramsdale J et al (2002) Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86:886–892

    Article  CAS  PubMed  Google Scholar 

  20. Chau GY, Lee AF, Tsay SH et al (2007) Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology 51:204–218

    Article  PubMed  Google Scholar 

  21. Hussein MR, Haemel AK, Wood GS (2003) Apoptosis and melanoma: molecular mechanisms. J Pathol 199:275–288

    Article  CAS  PubMed  Google Scholar 

  22. Ootsuka S, Asami S, Sasaki T et al (2007) Analyses of novel prognostic factors in neuroblastoma patients. Biol Pharm Bull 30:2294–2299

    Article  CAS  PubMed  Google Scholar 

  23. Troeger A, Siepermann M, Escherich G et al (2007) Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 92:1043–1050

    Article  CAS  PubMed  Google Scholar 

  24. Guo X, Goessl E, Jin G et al (2008) Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Res 28:9–14

    CAS  PubMed  Google Scholar 

  25. Leith JT, Faulkner LA, Papa G et al (1991) In vitro radiation survival parameters of human colon tumor cells. Int J Radiat Oncol Biol Phys 20:203–206

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Oncology, Nanjing General Hospital of PLA, 210002, Nanjing, Jiangsu, China

    C. Xiaoyuan, C. Longbang, W. Jinghua, G. Xiaoxiang, G. Huaicheng, Z. Qun & S. Haizhu

Authors
  1. C. Xiaoyuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Longbang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Jinghua
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Xiaoxiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Huaicheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z. Qun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Haizhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Xiaoyuan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xiaoyuan, C., Longbang, C., Jinghua, W. et al. Survivin: a potential prognostic marker and chemoradiotherapeutic target for colorectal cancer. Ir J Med Sci 179, 327–335 (2010). https://doi.org/10.1007/s11845-009-0448-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-009-0448-8

Keywords

Search

Navigation